Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial

To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days...

Full description

Saved in:

Bibliographic Details
Published in:	Drugs in R&D Vol. 5; no. 4; pp. 185 - 190
Main Authors:	Ragozzino, Giovanni, Mattera, Edi, Madrid, Elisa, Salomone, Patrizia, Fasano, Carmela, Gioia, Filomena, Acerra, Giusy, del Guercio, Raffaele, Federico, Pasquale
Format:	Journal Article
Language:	English
Published:	New Zealand 2004
Subjects:	Blood Glucose - drug effects Carnitine - administration & dosage Carnitine - analogs & derivatives Carnitine - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Humans Injections, Intravenous Male Middle Aged Peripheral Vascular Diseases - complications Peripheral Vascular Diseases - drug therapy Pilot Projects Treatment Outcome Vasodilator Agents - administration & dosage Vasodilator Agents - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1). Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported. This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1174-5886
DOI:	10.2165/00126839-200405040-00001